Stellar Biotechnologies, Inc, a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone805-488-2800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$210,000.00
Profitability
Miscellaneous
Employees25
Next Earnings Date11/29/2019 (Estimated)
OptionableNot Optionable
Stellar Biotechnologies (NASDAQ:SBOT) Frequently Asked Questions
What is Stellar Biotechnologies' stock symbol?
Stellar Biotechnologies trades on the NASDAQ under the ticker symbol "SBOT."
When did Stellar Biotechnologies' stock split? How did Stellar Biotechnologies' stock split work?
Stellar Biotechnologies's stock reverse split on the morning of Monday, May 7th 2018. The 1-7 reverse split was announced on Friday, April 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 4th 2018. An investor that had 100 shares of Stellar Biotechnologies stock prior to the reverse split would have 14 shares after the split.
How were Stellar Biotechnologies' earnings last quarter?
Stellar Biotechnologies Inc (NASDAQ:SBOT) released its earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by $0.05. The biotechnology company earned $0.12 million during the quarter, compared to analyst estimates of $0.11 million. Stellar Biotechnologies had a negative return on equity of 51.12% and a negative net margin of 1,782.64%. View Stellar Biotechnologies' Earnings History.
When is Stellar Biotechnologies' next earnings date?
Has Stellar Biotechnologies been receiving favorable news coverage?
Headlines about SBOT stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Stellar Biotechnologies earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Stellar Biotechnologies.
Who are some of Stellar Biotechnologies' key competitors?
Some companies that are related to Stellar Biotechnologies include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), Eli Lilly And Co (LLY), AbbVie (ABBV), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY) and Celgene (CELG).
What other stocks do shareholders of Stellar Biotechnologies own?
Who are Stellar Biotechnologies' key executives?
Stellar Biotechnologies' management team includes the folowing people:
- Mr. Frank R. Oakes, Chairman, Pres & CEO (Age 69)
- Ms. Kathi Niffenegger CPA, CFO & Corp. Sec. (Age 62)
- Mr. Gary Koppenjan, Sr. Director of Investor Relations & Communications
- Brando Lincicum, Exec. Director of Aquaculture and Facility Operations
How big of a company is Stellar Biotechnologies?
Stellar Biotechnologies has a market capitalization of $0.00 and generates $210,000.00 in revenue each year. The biotechnology company earns $-5,030,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Stellar Biotechnologies employs 25 workers across the globe.View Additional Information About Stellar Biotechnologies.
What is Stellar Biotechnologies' official website?
How can I contact Stellar Biotechnologies?
Stellar Biotechnologies' mailing address is 332 EAST SCOTT STREET, PORT HUENEME CA, 93041. The biotechnology company can be reached via phone at 805-488-2800 or via email at [email protected]
MarketBeat Community Rating for Stellar Biotechnologies (NASDAQ SBOT)
MarketBeat's community ratings are surveys of what our community members think about Stellar Biotechnologies and other stocks. Vote "Outperform" if you believe SBOT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBOT will underperform the S&P 500 over the long term. You may vote once every thirty days.
